We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Are Lloyds Banking Group PLC And GlaxoSmithKline plc Bargain Buys For 2016?

Why Lloyds Banking Group PLC (LON:LLOY) and GlaxoSmithKline plc (LON:GSK) could reverse recent losses and beat the market in 2016.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Lloyds Banking Group (LSE: LLOY) and GlaxoSmithKline (LSE: GSK) may beat the FTSE 100 this year, but both stocks look likely to end the year lower than they started. Will they bounce back next year?

GlaxoSmithKline: On the rise

Shares in Glaxo are now down by nearly 25% from the highs seen in 2013. In fairness, this weakness has been justified by the firm’s recent financial performance, which has been disappointing.

Should you buy Lloyds Banking Group Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Glaxo’s post-tax profits plunged from £5.436bn in 2013 to just £2.756bn in 2014 as the impact of patent losses on key products affected sales.

However, the situation does seem to be improving. Glaxo has now completed a major asset swap with Novartis and last week announced a new deal to acquire additional HIV products. Analysts expect full-year profits to rise by 34% to £3.691bn this year, and by a further 11% to £4.099bn in 2016.

The firm has managed to avoid cutting its dividend so far and currently offers a prospective yield of 6.1% for 2016. Big long-term backers of GlaxoSmithKline, such as star fund manager Neil Woodford, have been buying more shares this year.

Mr Woodford’s view is that short-term headwinds are overshadowing the much greater long-term earning power of Glaxo’s portfolio. This is a view I share.

For investors looking for long-term income and growth, I think that now could prove to be a good time to buy GlaxoSmithKline.

Lloyds: Stock overhang

I believe that Lloyds investors are suffering from a problem that more commonly affects shareholders in small cap companies – a stock overhang.

The overhang comes in the form of the government, which is gradually pumping its Lloyds shares back into the market. Since the end of May, the Treasury has sold 9% of Lloyds shares. That’s equivalent to £5.2bn worth of shares at today’s price.

This means that big institutional buyers of the stock have been guaranteed a good supply of Lloyds shares, without pushing up the price.

However, the share sale has been paused recently as Lloyds shares have been selling below 73.6p. This is the price at which the government bailed out Lloyds in 2008. The bankers handling the sale have been told only to sell Lloyds stock when the price is above this level.

I suspect that this requirement means Lloyds’ share price will find support at around 70p, as the volume of shares available for institutions to buy is much lower now that the government isn’t selling.

However, I also suspect that Lloyds shares won’t rise much above 73.6p until the government has sold all of its shares, which it hopes to do in 2016.

That’s why I believe now could be a good time to buy. At today’s price of 72p, Lloyds offers a prospective yield of 5.1% for 2016, and a modest forecast P/E of 9.5. The shares are supported by a book value of 68p and by 55p per share of tangible assets.

In my view Lloyds currently offers more upside potential than downside risk, and could prove a profitable buy for 2016.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up as a woman counts out modern British banknotes.
Investing Articles

How to buy growth stocks at below-market prices

Don’t want to pay market prices for growth stocks? Here's a sneaky strategy investors can use to get deals at…

Read more »

CEO Mark Zuckerberg at F8 2019 event
Investing Articles

Are Meta shares at the start of a comeback?

Shares in Meta Platforms have been held back by the firm’s high-risk approach to AI. But is this the moment…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

With dividend yields averaging above 7%, are these 2 UK shares worth considering?

Muhammad Cheema looks at two UK shares: ITV and Legal & General. With yields of 6.1% and 8.1%, should investors…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

How much do you need to invest in dividend stocks to be able to retire?

Some 77% of people in the UK won't have enough income to manage a moderate retirement. Here’s how dividend stocks…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

FTSE 250 stock CMC’s shares have rocketed 51%! What’s going on?

CMC Markets' shares have surged by double-digits today after a strong full-year trading update. Is the FTSE 250 company now…

Read more »

A row of satellite radars at night
Investing Articles

Will I buy SpaceX at £100 a share in my SIPP?

Ben McPoland is considering adding SpaceX stock to his SIPP on 12 June. Might this be a no-brainer buy-and-hold opportunity?

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

Aberdeen shares are back in the FTSE 100 — is this turnaround stock just getting started?

Following its return to the FTSE 100, Andrew Mackie examines whether Aberdeen's shares could be on the cusp of a…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

Down 65% with a 5.65% yield! Is this dividend share a once-in-a-decade buy? 

Harvey Jones says this dividend share is still posting decent profits at a challenging time. Its low valuation and high…

Read more »